Knockdown of Alpha-1 Antitrypsin with antisense oligonucleotide does not exacerbate smoke induced lung injury.
Animals
Disease Models, Animal
Gene Knockdown Techniques
Humans
Injections, Subcutaneous
Male
Mice
Mutation
Oligonucleotides, Antisense
/ administration & dosage
Pancreatic Elastase
/ metabolism
Pulmonary Disease, Chronic Obstructive
/ etiology
Random Allocation
Smoke Inhalation Injury
/ genetics
alpha 1-Antitrypsin
/ genetics
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
07
2020
accepted:
12
01
2021
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
24
7
2021
Statut:
epublish
Résumé
Alpha-1 Antitrypsin (AAT) is a serum protease inhibitor that regulates increased lung protease production induced by cigarette smoking. Mutations in the Serpina1 gene cause AAT to form hepatoxic polymers, which can lead to reduced availability for the protein's primary function and severe liver disease. An AAT antisense oligonucleotide (ASO) was previously identified to be beneficial for the AATD liver disease by blocking the mutated AAT transcripts. Here we hypothesized that knockdown of AAT aggravates murine lung injury during smoke exposure and acute exacerbations of chronic obstructive pulmonary disease (COPD). C57BL/6J mice were randomly divided into 4 groups each for the smoking and smoke-flu injury models. The ASO and control (No-ASO) were injected subcutaneously starting with smoking or four days prior to influenza infection and then injected weekly at 50 mg/kg body weight. ASO treatment during a 3-month smoke exposure significantly decreased the serum and lung AAT expression, resulting in increased Cela1 expression and elastase activity. However, despite the decrease in AAT, neither the inflammatory cell counts in the bronchoalveolar lavage fluid (BALF) nor the lung structural changes were significantly worsened by ASO treatment. We observed significant differences in inflammation and emphysema due to smoke exposure, but did not observe an ASO treatment effect. Similarly, with the smoke-flu model, differences were only observed between smoke-flu and room air controls, but not as a result of ASO treatment. Off-target effects or compensatory mechanisms may account for this finding. Alternatively, the reduction of AAT with ASO treatment, while sufficient to protect from liver injury, may not be robust enough to lead to lung injury. The results also suggest that previously described AAT ASO treatment for AAT mutation related liver disease may attenuate hepatic injury without being detrimental to the lungs. These potential mechanisms need to be further investigated in order to fully understand the impact of AAT inhibition on protease-antiprotease imbalance in the murine smoke exposure model.
Identifiants
pubmed: 33539438
doi: 10.1371/journal.pone.0246040
pii: PONE-D-20-23075
pmc: PMC7861354
doi:
Substances chimiques
Oligonucleotides, Antisense
0
Serpina1a protein, mouse
0
alpha 1-Antitrypsin
0
CELA1 protein, mouse
EC 3.4.21.36
Pancreatic Elastase
EC 3.4.21.36
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0246040Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL086936
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL120826
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Chest. 1986 Mar;89(3):370-3
pubmed: 3485034
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):2788-2793
pubmed: 29453277
Am J Respir Cell Mol Biol. 2018 Aug;59(2):167-178
pubmed: 29420065
Ann Am Thorac Soc. 2016 Aug;13 Suppl 4:S297-304
pubmed: 27564664
Methods Mol Biol. 2017;1639:9-19
pubmed: 28752442
Respirology. 2010 Apr;15(3):536-42
pubmed: 20415983
J Pediatr. 2013 Aug;163(2):320-6
pubmed: 23664631
Semin Respir Crit Care Med. 2005 Apr;26(2):142-53
pubmed: 16088433
Am J Physiol Lung Cell Mol Physiol. 2014 Jun 15;306(12):L1104-16
pubmed: 24793170
Am J Respir Crit Care Med. 2003 Oct 1;168(7):818-900
pubmed: 14522813
Adv Drug Deliv Rev. 2015 Jun 29;87:90-103
pubmed: 25797014
Rare Dis. 2014 Mar 12;2:e28511
pubmed: 25054094
Chronic Obstr Pulm Dis. 2016 Nov 18;4(1):34-44
pubmed: 28848909
Respir Res. 2015 Jul 15;16:85
pubmed: 26169056
Clin Chest Med. 2014 Mar;35(1):157-63
pubmed: 24507843
COPD. 2015 May;12 Suppl 1:58-62
pubmed: 25938294
Agents Actions Suppl. 1993;40:3-12
pubmed: 8480553
BMC Pulm Med. 2013 Jun 04;13:36
pubmed: 23734748
Am J Respir Cell Mol Biol. 2016 Nov;55(5):708-715
pubmed: 27373990
Am J Respir Crit Care Med. 2016 Apr 15;193(8):825-34
pubmed: 26599602
Curr Mol Med. 2012 Aug;12(7):807-14
pubmed: 22697347
Lung. 1990;168 Suppl:552-64
pubmed: 2117164
Pneumonol Alergol Pol. 2011;79(3):207-14
pubmed: 21509733